Kardigan, Inc. quarterly report, Q2 FY2026

Business Context and Reporting Period

Kardigan, Inc. is a clinical-stage precision therapeutics company focused on developing medicines for cardiovascular diseases. The company operates as a single segment and is headquartered in Princeton, New Jersey. This filing covers the quarterly period ended June 30, 2026. A significant corporate event during this period was the completion of the company's Initial Public Offering (IPO) on June 22, 2026, which converted all outstanding redeemable convertible preferred stock into common stock.

Key Financial Metrics

Metric Six Months Ended June 30, 2026 Six Months Ended June 30, 2025
Revenue $0 $0
Net Loss $(172.3) million $(75.5) million
Operating Expenses $177.5 million $83.2 million
Research & Development (R&D) $101.4 million $54.6 million
General & Administrative (G&A) $32.5 million $28.6 million
Cash, Cash Equivalents & Investments $660.7 million $331.7 million
Accumulated Deficit $(453.4) million $(281.1) million
Net Cash Used in Operating Activities $(107.3) million $(52.8) million
Net Cash Provided by Financing Activities $437.2 million $100.2 million

Material Changes vs. Prior Period

  • Net Loss Increase: Net loss increased by approximately $96.8 million (128%) compared to the prior year period. This was primarily driven by a $43.5 million increase in the fair value of contingent milestone liabilities and higher R&D expenses.
  • Contingent Milestone Liability: A non-cash charge of $43.5 million was recorded due to the remeasurement of contingent milestone liabilities associated with the Prolaio acquisition. This increase was driven by the company's higher market valuation following the IPO, which increased the probability of achieving valuation-based milestones.
  • R&D Expenses: R&D expenses increased by $46.8 million (86%), reflecting expanded clinical activity across the Danicamtiv, Ataciguat, and Tonlamarsen programs, as well as increased personnel costs.
  • Liquidity Position: Cash, cash equivalents, and investments increased significantly to $660.7 million from $331.7 million, primarily due to net proceeds of $422.4 million from the IPO.
  • Capital Structure: All redeemable convertible preferred stock was converted to common stock upon the IPO closing. The company now has 93.5 million shares of common stock outstanding.

Guidance, Outlook, and Risks

  • Clinical Outlook: The company expects to report clinical data from its three late-stage programs (Danicamtiv, Ataciguat, and Tonlamarsen) in the first half of 2027. Enrollment for the Phase 2b KINSHIP-DCM trial (Danicamtiv) is underway, and the KARDINAL-ASH Phase 2 trial (Tonlamarsen) has randomized its first patient.
  • Liquidity Runway: Management believes existing cash resources of $660.7 million are sufficient to fund operations for at least 12 months from the filing date.
  • Future Funding: The company anticipates incurring significant losses for the foreseeable future and will require substantial additional capital to advance clinical trials and commercialization efforts. Future financing may involve equity or debt offerings, which could result in dilution.
  • Key Risks:
    • Clinical Failure: High risk of failure in clinical trials, which could materially harm the business.
    • Regulatory Uncertainty: Dependence on FDA and EMA approvals, which are lengthy and unpredictable.
    • Contingent Liabilities: Significant exposure to fair value changes in contingent milestone liabilities tied to market valuation thresholds.
    • Third-Party Dependence: Reliance on third-party manufacturers and CROs for clinical trials and drug supply.

Investor Verification Checklist

  • Verify the specific terms and probability assumptions used to calculate the $43.5 million increase in contingent milestone liabilities.
  • Confirm the enrollment status and timeline for the KINSHIP-DCM, KATALYST-AV, and KARDINAL-ASH clinical trials.
  • Review the details of the Prolaio acquisition amendment and the specific valuation thresholds required to trigger the $200 million in potential milestone payments.
  • Assess the company's burn rate and the sufficiency of the $660.7 million cash balance relative to the projected costs of advancing three late-stage programs simultaneously.
  • Examine the licensing agreements with BMS, Ionis, Sanofi, and Mayo for potential future royalty and milestone payment obligations.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.